PMID- 38100778
OWN - NLM
STAT- MEDLINE
DCOM- 20231218
LR  - 20231218
IS  - 1533-712X (Electronic)
IS  - 0271-0749 (Linking)
VI  - 44
IP  - 1
DP  - 2024 Jan-Feb 01
TI  - A Narrative Review on Pharmacogenomics in Psychiatry: Scientific Definitions, 
      Principles, and Practical Resources.
PG  - 49-56
LID - 10.1097/JCP.0000000000001795 [doi]
AB  - PURPOSE/BACKGROUND: Pharmacogenetics (PGx) studies the genetic factors underlying 
      interindividual variability in drug response. Only a few countries around the 
      world are already using PGx testing in psychiatric clinical practice, whereas 
      others are still far from adopting it. The main barrier to the clinical adoption 
      of PGx testing seems to be the limited knowledge among psychiatrists regarding 
      the clinical relevance of specific genetic variants to personalize therapies and 
      the accessibility of PGx data. This review aims at further highlighting the 
      importance of PGx-driven clinical decision making for psychotropic medications 
      and raising psychiatrists' awareness of the value of PGx testing in psychiatry. 
      METHODS/PROCEDURES: We summarize the genes for which substantial evidence exists 
      about the clinical utility of integrating their PGx testing in psychiatry. 
      Specifically, we systematically describe the functional role of clinically 
      relevant allelic variants, their frequency across different ethnic groups, and 
      how they contribute to classify patients in relation to their capability in 
      metabolizing psychotropic drugs. FINDINGS/RESULTS: Briefly, clinical guidelines 
      recommend considering PGx testing of the cytochrome class 2 C9 (CYP2C9), C19 
      (CYP2C19), and D6 (CYP2D6) genes and the human leukocyte antigen (HLA)-A and -B 
      genes for several psychotropic drugs. IMPLICATIONS/CONCLUSIONS: Extensive studies 
      have been carried out to provide a solid rationale for the inclusion of PGx 
      testing in psychiatry. Comprehensive clinical guidelines are readily accessible 
      to support health care providers in tailoring the prescription of psychotropic 
      drugs based on patient's genotype information. This approach presents a tangible 
      opportunity to significantly improve individual responses to psychiatric 
      medications.
CI  - Copyright (c) 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Palumbo, Sara
AU  - Palumbo S
AD  - From the Department of Clinical and Experimental Medicine, University of Pisa, 
      Pisa, Italy.
FAU - Mariotti, Veronica
AU  - Mariotti V
FAU - Pellegrini, Silvia
AU  - Pellegrini S
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231112
PL  - United States
TA  - J Clin Psychopharmacol
JT  - Journal of clinical psychopharmacology
JID - 8109496
RN  - 0 (Psychotropic Drugs)
SB  - IM
MH  - Humans
MH  - *Pharmacogenetics
MH  - Precision Medicine
MH  - *Psychiatry
MH  - Genotype
MH  - Psychotropic Drugs/pharmacology/therapeutic use
EDAT- 2023/12/15 18:41
MHDA- 2023/12/18 06:42
CRDT- 2023/12/15 17:20
PHST- 2023/12/18 06:42 [medline]
PHST- 2023/12/15 18:41 [pubmed]
PHST- 2023/12/15 17:20 [entrez]
AID - 00004714-202401000-00010 [pii]
AID - 10.1097/JCP.0000000000001795 [doi]
PST - ppublish
SO  - J Clin Psychopharmacol. 2024 Jan-Feb 01;44(1):49-56. doi: 
      10.1097/JCP.0000000000001795. Epub 2023 Nov 12.